911 reports of this reaction
2.2% of all SOFOSBUVIR reports
#9 most reported adverse reaction
HEPATOCELLULAR CARCINOMA is the #9 most commonly reported adverse reaction for SOFOSBUVIR, manufactured by Gilead Sciences, Inc.. There are 911 FDA adverse event reports linking SOFOSBUVIR to HEPATOCELLULAR CARCINOMA. This represents approximately 2.2% of all 41,429 adverse event reports for this drug.
Patients taking SOFOSBUVIR who experience hepatocellular carcinoma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEPATOCELLULAR CARCINOMA is a less commonly reported adverse event for SOFOSBUVIR, but still significant enough to appear in the safety profile.
In addition to hepatocellular carcinoma, the following adverse reactions have been reported for SOFOSBUVIR:
The following drugs have also been linked to hepatocellular carcinoma in FDA adverse event reports:
HEPATOCELLULAR CARCINOMA has been reported as an adverse event in 911 FDA reports for SOFOSBUVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEPATOCELLULAR CARCINOMA accounts for approximately 2.2% of all adverse event reports for SOFOSBUVIR, making it a notable side effect.
If you experience hepatocellular carcinoma while taking SOFOSBUVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.